Drug maker Merck is facing criticism that it is overpaying for its planned $8.4 billion purchase of Cubist after a court ruled that the company’s flagship antibiotic could be subject to generic competition.
WSJ.com: Law, Wall Street Journal: Business: Law
Tue, 12/09/2014 - 12:24pm
Drug maker Merck is facing criticism that it is overpaying for its planned $8.4 billion purchase of Cubist after a court ruled that the company’s flagship antibiotic could be subject to generic competition.